Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07567001 · ClinicalTrials.gov registry record · Phase 3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 5,610
- Enrollment target
NCT07567001 is a Phase 3 study that is actively recruiting participants, run by Novo Nordisk A/S. The registered enrollment target is 5,610 participants.
The verdict
NCT07567001, a Phase 3 study, is actively recruiting participants, sponsored by Novo Nordisk A/S.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 5,610 participants
- Enrollment target
Study Summary
This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have HFpEF or HFmrEF and excess body weight. Participants will get NNC0487-0111 or placebo by injection once a week. Which treatment participants get is decided by chance. NNC0487-0111 is a new medicine that doctors cannot prescribe yet, but it has been tested in people before.
Interventions
- DRUG Placebo
- DRUG NNC0487-0111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,610 participants |
| Start Date | 2026-05-11 |
| Est. Completion | 2029-08-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07567001
The ClinicalTrials.gov registry entry for NCT07567001 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 5,610 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07567001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07567001 about?
NCT07567001 is a clinical study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity". This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to fi...
What is the current status of trial NCT07567001?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,610 participants. The study started on 2026-05-11. Estimated completion is 2029-08-15.
What interventions are being tested in trial NCT07567001?
The interventions under investigation include: Placebo (DRUG), NNC0487-0111 (DRUG).
Who is sponsoring clinical trial NCT07567001?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.